FDA approves generic version of twice-yearly HIV-prevention injection lenacapavir

The U.S. Food and Drug Administration (FDA) has approved a generic version of lenacapavir, an injectable drug used to prevent HIV. STAT News and the Associated Press (AP) both reported the decision.

Lenacapavir is given twice a year, or once every six months. STAT News gives the generic's price as $40 per person per year. The AP headline calls it a "cheap version". The reports reviewed by Vocemundi do not give a price for the brand-name version for comparison.

What is reported

According to STAT News, the approval was granted to Dr. Reddy's Laboratories. STAT News describes the company as one of the world's largest generic drugmakers. In its report dated 2 November 2026, STAT News said the company plans to start shipping the medicine next month.

STAT News says the $40 annual cost is comparable to the cost of daily HIV-prevention tablets. It calls the approval a key step in widening access to the drug for dozens of low- and middle-income countries. According to STAT News, several global health organizations have helped drive the effort to make the drug available quickly in lower-income countries.

According to STAT News, lenacapavir offers virtually complete protection against contracting HIV. STAT News says the brand-name version is known in the U.S. as Yetzugo. According to STAT News, it is marketed by Gilead Sciences and was approved by the FDA last year. The AP describes lenacapavir as the world's only twice-a-year shot to prevent HIV.

What is disputed

The two reports describe the type of approval differently. STAT News says the FDA granted tentative approval to Dr. Reddy's Laboratories. The AP summary describes it as an approval and does not say it is tentative. The reports reviewed by Vocemundi do not explain this difference.

What is not known

The reports reviewed by Vocemundi do not include an FDA statement or document on the decision. They do not give the exact date of the decision. They do not explain what "tentative approval" means in this case or whether any conditions apply.

The reports do not include a statement from Dr. Reddy's Laboratories confirming its shipping plans, its pricing or the countries it will supply. They do not name the countries expected to receive the drug, expected supply volumes, or the global health organizations involved. They do not include a response from Gilead Sciences. They do not say whether other generic manufacturers have received or are seeking similar approval.

Vocemundi reviewed only part of the STAT News article, as the rest is behind a subscriber paywall. Only the headline and summary of the AP report were available.

Analysis

If the reported $40 annual price and shipping plans hold, a twice-yearly injection could become a lower-cost prevention option in countries where daily tablets are the main alternative. Several factors remain open. The meaning of the approval's reported "tentative" status is not explained in the reports reviewed, and it may affect where and how the generic can be used. Supply volumes, recipient countries and the role of global health organizations are not yet described. Responses from Gilead Sciences and any moves by other generic makers could also shape access. These points will determine how widely the drug reaches people who need it.

Produced by the Vocemundi newsroom with AI assistance.

Transparency note: objections from our AI reviewers

Objections raised before publication:

• Vocemundi automatic checks: Tribunal needs a fix

No reviewer declined to review it.

Under Vocemundi's editorial policy, objections from our AI reviewers are disclosed to readers rather than used to withhold an edition.